Oroxylin a prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF-κB signaling

Authors

  • Jing Yao,

    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Rong Hu,

    1. School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Jie Sun,

    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Biqi Lin,

    1. School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Li Zhao,

    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Yunying Sha,

    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Binbin Zhu,

    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Qi-Dong You,

    1. School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of, China
    Search for more papers by this author
  • Tianhua Yan,

    Corresponding author
    1. Department of Physiology, China Pharmaceutical University, Nanjing, People's Republic of, China
    • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, P.O. Box 209, 24 Tongjia Xiang, Nanjing 210009, People's Republic of China.

      Department of Physiology, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People's Republic of China.

    Search for more papers by this author
  • Qing-Long Guo

    Corresponding author
    1. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of, China
    • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, P.O. Box 209, 24 Tongjia Xiang, Nanjing 210009, People's Republic of China.

      Department of Physiology, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People's Republic of China.

    Search for more papers by this author

  • Jing Yao and Rong Hu contributed equally to this article.

Abstract

Increasing evidence suggests that inflammatory microenvironment plays a critical role at different stages of tumor development. However, the molecular mechanisms of the interaction between inflammation and proliferation of cancer cells remain poorly defined. Here we reported the inhibitory effects of oroxylin A on the inflammation-stimulated proliferation of tumor cells and delineated the mechanism of its action. The results indicated that treatment with oroxylin A inhibited NF-κB p65 nuclear translocation and phosphorylation of IκBα and IKKα/β in both human colon tumor HCT116 cells and human monocytes THP-1 cells. In addition, in THP-1 cells, oroxylin A significantly suppressed lipopolysaccharide (LPS)-induced secretion of prototypical proinflammatory cytokine IL-6 but not IL-1β, and it was confirmed at the transcription level. Moreover, oroxylin A inhibited the proliferation of HCT116 cells stimulated by LPS-induced THP-1 cells in co-culture microenvironment. In summary, oroxylin A modulated NF-κB signaling pathway involved in inflammation-induced cancer initiation and progression and therefore could be a potential cancer chemoprevention agent for inflammation-related cancer. © 2012 Wiley Periodicals, Inc.

Ancillary